Eli Lilly said preliminary data from a late-stage study showed its weight-loss drug significantly reduced the risk of progression to type 2 diabetes among adults with prediabetes and obesity or overweight.
Related Posts
Financial Services Roundup: Market Talk
Find insight on UOB, Manulife Financial and more in the latest Market Talks covering financial services.
U.S. Blocks Imports From 37 More Chinese Companies Over Forced-Labor Concerns
- staff
- January 15, 2025
- 0
The latest additions targeted Chinese companies in the critical-minerals, textiles and solar-technology industries.
Ford Shrinks Its EV Rollout Plans as Demand Lags
The automaker expects to take $1.9 billion in related special charges and write-downs as automakers continue adjusting their EV plans because of softer-than-expected demand.